1. Möller HJ, Bandelow B, Bauer M, Hampel H, Herpertz SC, Soyka M, Maier W (2014) DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences—part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive–compulsive disorders, trauma-and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-014-0521-9
2. Schennach R, Riedel M, Obermeier M, Spellmann I, Musil R, Jäger M, Möller HJ (2014) What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-014-0528-2
3. Krzyżanowska M, Steiner J, Brisch R, Mawrin C, Busse S, Braun K, Gos T (2014) Ribosomal DNA transcription in the dorsal raphe nucleus is increased in residual but not in paranoid schizophrenia. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-014-0518-4
4. Kittel-Schneider S, Wobrock T, Scherk H, Schneider-Axmann T, Trost S, Zilles D, Reif A (2014) Influence of DGKH variants on amygdala volume in patients with bipolar affective disorder and schizophrenia. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-014-0513-9
5. Hass J, Walton E, Kirsten H, Turner J, Wolthusen R, Roessner V, Ehrlich S (2014) Complexin2 modulates working memory-related neural activity in patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. doi: 10.1007/s00406-014-0550-4